David A. Pfister
Papers
2
Total Citations
23
H-Index
2
About
David A. Pfister is a leading urologic oncologist whose research focuses on refining surgical treatments for testicular cancer, particularly seminoma. His major contributions center on the role of nerve-sparing retroperitoneal lymph node dissection (RPLND) as an alternative to traditional chemotherapy or radiation for patients with clinical stage IIA/B seminoma. As principal investigator of the landmark COTRIMS trial, Pfister has pioneered evidence that this surgical approach can achieve high cure rates—90–94% for stage IIA and 82–90% for stage IIB—while minimizing long-term toxicity. His 2022 paper on the COTRIMS trial (15 citations) and its 2023 interim analysis (8 citations) have reshaped clinical guidelines, offering patients a treatment option that avoids the systemic side effects of chemotherapy. Pfister’s work is notable for challenging decades-old paradigms, demonstrating that surgery can be both curative and nerve-sparing, preserving quality of life. His research has been instrumental in establishing RPLND as a viable first-line therapy, impacting urologic oncology practice worldwide. For students and researchers, Pfister exemplifies how rigorous clinical trials can transform standard care in genitourinary malignancies.
Research Focus
Key Achievements
Top Papers
- 1
- 2